Franklin Resources Inc. Boosts Holdings in TG Therapeutics, Inc. $TGTX

Franklin Resources Inc. boosted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 25.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 91,387 shares of the biopharmaceutical company’s stock after purchasing an additional 18,452 shares during the quarter. Franklin Resources Inc.’s holdings in TG Therapeutics were worth $3,289,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Teacher Retirement System of Texas lifted its stake in shares of TG Therapeutics by 1.0% in the second quarter. Teacher Retirement System of Texas now owns 40,212 shares of the biopharmaceutical company’s stock worth $1,447,000 after buying an additional 417 shares in the last quarter. Kingswood Wealth Advisors LLC raised its holdings in TG Therapeutics by 6.4% in the 2nd quarter. Kingswood Wealth Advisors LLC now owns 8,284 shares of the biopharmaceutical company’s stock worth $298,000 after acquiring an additional 500 shares during the last quarter. Louisiana State Employees Retirement System lifted its position in TG Therapeutics by 0.8% in the 2nd quarter. Louisiana State Employees Retirement System now owns 63,400 shares of the biopharmaceutical company’s stock valued at $2,282,000 after acquiring an additional 500 shares in the last quarter. New York State Teachers Retirement System boosted its stake in TG Therapeutics by 0.4% during the 2nd quarter. New York State Teachers Retirement System now owns 120,864 shares of the biopharmaceutical company’s stock valued at $4,350,000 after purchasing an additional 500 shares during the last quarter. Finally, Amalgamated Bank boosted its stake in TG Therapeutics by 1.3% during the 2nd quarter. Amalgamated Bank now owns 38,824 shares of the biopharmaceutical company’s stock valued at $1,397,000 after purchasing an additional 501 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

Insider Buying and Selling at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of TG Therapeutics stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the transaction, the director owned 94,061 shares in the company, valued at $3,032,526.64. This trade represents a 18.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Yann Echelard sold 5,000 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $32.57, for a total value of $162,850.00. Following the completion of the sale, the director owned 223,816 shares of the company’s stock, valued at $7,289,687.12. This trade represents a 2.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 10.64% of the company’s stock.

TG Therapeutics Trading Down 3.3%

Shares of NASDAQ:TGTX opened at $30.63 on Wednesday. The stock has a market capitalization of $4.86 billion, a price-to-earnings ratio of 82.78 and a beta of 1.95. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The stock’s 50-day simple moving average is $33.70 and its two-hundred day simple moving average is $33.87. TG Therapeutics, Inc. has a 52-week low of $25.28 and a 52-week high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, beating the consensus estimate of $0.24 by $2.19. The firm had revenue of $161.71 million during the quarter, compared to analyst estimates of $152.12 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The business’s revenue for the quarter was up 92.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.02 EPS. Analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on TGTX shares. HC Wainwright began coverage on TG Therapeutics in a research note on Monday, October 6th. They issued a “buy” rating and a $60.00 price target for the company. JPMorgan Chase & Co. boosted their target price on TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Wall Street Zen upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. B. Riley upgraded shares of TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $50.25.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.